Stock Details

Enter Company or Symbol. Press down arrow for suggestions, or Escape to return to entry field.

RELATED RESOURCES

Change Text Size:

BRIEF-Keros Therapeutics Presents Results From Preclinical Study Of Rker-012 In Pulmonary Arterial Hypertension At Pulmonary Hypertension Association International Conference And Scientific Sessions

BY Reuters
— 8:28 AM ET 06/13/2022

June 13 (Reuters) - Keros Therapeutics Inc (KROS):

* KEROS THERAPEUTICS PRESENTS RESULTS FROM A PRECLINICAL STUDY OF RKER-012 IN PULMONARY ARTERIAL HYPERTENSION AT PULMONARY HYPERTENSION ASSOCIATION INTERNATIONAL CONFERENCE AND SCIENTIFIC SESSIONS Source text for Eikon: Further company coverage:

Copyright © Reuters 2008. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

More KROS News

Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the Pulmonary Hypertension Association International Conference and Scientific Sessions
GlobeNewswire - 8:00 AM ET 06/13/2022
Stocks That Hit 52-Week Lows On Friday
Benzinga - 11:45 AM ET 06/10/2022
Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 27th Annual Congress of the European Hematology Association
GlobeNewswire - 6:00 AM ET 06/10/2022